PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00455546|
Recruitment Status : Completed
First Posted : April 3, 2007
Last Update Posted : February 2, 2010
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease (CAD)||Drug: A-002||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||PLASMA Trial: Phospholipase Levels And Serological Markers of Atherosclerosis: A Dose-Response Clinical Pharmacology Study of A-002 In Subjects With Stable Coronary Artery Disease|
|Study Start Date :||April 2007|
|Study Completion Date :||September 2007|
- Comparison of active and placebo treatments with respect to change from Baseline to Week 8 in sPLA2 levels and activity.
- Comparison of active and placebo treatments with respect to change in: Inflammatory markers, lipid and biochemical parameters, and LDL and HDL subclasses.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00455546
Show 36 Study Locations